Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Zogenix Inc. : Zogenix Announces Conference Call and Webcast to Present First Quarter 2013 Financial Results

05/03/2013 | 08:40am US/Eastern
Conference Call Scheduled for May 9, 2013 at 4:30 pm ET

SAN DIEGO, May 3, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release financial results for the first quarter ended March 31, 2013, after the market closes on Thursday, May 9, 2013, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these financial results and provide a company update.

To access the live webcast please visit the Company's Investor Relations website at ir.zogenix.com, and to participate, please dial (866) 318-8616 (U.S.) or (617) 399-5135 (International); participant passcode: 65838569.

The conference call will be hosted by Chief Executive Officer Roger L. Hawley, President Stephen J. Farr, Ph.D., and Executive Vice President and Chief Financial Officer Ann Rhoads.

A replay of the conference call will be available beginning May 9, 2013 at 6:30 p.m. ET (3:30 p.m. PT) until May 16, 2013, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 23471504. A replay of the webcast will also be accessible on the Investor Relations website for one month, through June 9, 2013.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, Zohydro™ ER (hydrocodone bitartrate), is an oral, extended-release formulation of various strengths of hydrocodone, without acetaminophen, intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER. Zogenix's second investigational product candidate, Relday™, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia; an investigational new drug application was submitted to the FDA in May 2012. For additional information, please visit www.zogenix.com.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Caitlin Cox | The Ruth Group
         646.536.7033 | ccox@theruthgroup.com
Zogenix
distributed by
React to this article
Latest news
Date Title
07:24p SALT LAKE COMIC CON : ’s FanX 2015 Takes Flight Today
07:23p GATEKEEPER SYSTEMS INC : Gatekeeper Systems Receives Notice of Rejection of All Bids From Fort Worth Independent School District
07:22p FIRST FINANCIAL BANCORP : tops 4Q profit forecasts
07:22p AVIAT NETWORKS : reports 2Q loss
07:22p HYUNDAI HCN : Shah, Mehmood shine in WPCA league
07:22p CONSUMER PORTFOLIO SERVICES : INVESTOR ALERT: Investigation of Consumer Portfolio Services, Inc. Announced by Glancy Binkow & Goldberg LLP
07:21p UNILIFE : Announces Public Offering of Common Stock
07:21p JP ENERGY PARTNERS : Announces First Distribution
07:21p UNITED COMPANY RUSAL PLC : Continuing Connected Transactions Transportation Contracts
07:20p GATEKEEPER SYSTEMS : Receives Notice of Rejection of All Bids From Fort Worth Independent School District
Latest news
Advertisement
Hot News 
GROUPE STERIA : Sopra Steria Group: Financial calendar 2015
NEXT FIFTEEN COMMUNICATIONS : Raises GBP4.3 Million, To Beat Expectations (ALLISS)
PERFORMANT FINANCIAL : Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Unregistered Sale of Equity Securities, Other Events, Financial Statements and Exhibits (form 8-K)
VENAXIS : Other Events, Financial Statements and Exhibits (form 8-K)
GEVO : Announces Pricing of Public Offering of Common Stock and Warrants
Most Read News
06:24p Wall Street finishes higher in afternoon rally as oil gains
06:39p Cheaper gasoline helps Visa report better-than-expected profit
06:46pDJINTERCEPT PHARMACEUTICALS : Says FDA Grants Breakthrough Status
06:18p KINDER MORGAN : Taking on the pipeline; Residents plot course of action against Kinder Morgan
06:35pDJShake Shack Prices IPO at $21, Above Expectations, Source Says -- 2nd Update
Most recommended articles
07:19p Slowing Japan inflation keeps BOJ under pressure but output rebounds
07:17p Japan factory output rises 1.0 pct in December
07:15pDJPlunging Oil Continues to Weigh on Japan Inflation
07:14pDJAmazon's Profit Drops Less Than Expected -- 4th Update
07:10p South Korea factory output growth at over five-year high, recovery still fragile
Dynamic quotes  
ON
| OFF